Smith Nicola, Broadley Kenneth J
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff, UK.
Int Immunopharmacol. 2007 Feb;7(2):183-90. doi: 10.1016/j.intimp.2006.09.007. Epub 2006 Oct 6.
Antigen inhalation in patients with atopic asthma results in an early asthmatic response (EAR), accompanied by a late asthmatic response (LAR) in 60% of patients, airway hyperresponsiveness (AHR) and inflammatory cell infiltration to the lungs. An ideal animal model of asthma should, therefore, provide at least these 4 features consistently and reproducibly. The aim of this study was to optimise the ovalbumin (OA) sensitisation conditions, for achieving EAR, LAR, AHR and cell influx, in a guinea-pig model of asthma. Animals were sensitised with 10 micro g or 100 micro g OA, as either a single or booster (day 1 and day 5) injection. Airway responses to inhaled OA (10 micro g, 1 h) of actively sensitised, conscious guinea pigs were determined by whole body plethysmography as the change in specific airways conductance (sG(aw)) over a 12 h period and at 24 h. Bronchoconstriction by inhaled histamine (1 mM) was used to investigate AHR, and inflammatory cell influx was determined by bronchoalveolar lavage (BAL), both at 24 h post-challenge. A single sensitisation with 10 micro g OA did not reveal an EAR, LAR or AHR following exposure to OA. However, total and differential cell counts (eosinophils and macrophages) were significantly greater 24 h post-challenge, when compared to saline-challenged sensitised animals. The addition of a booster injection of 10 micro g revealed an EAR, but no LAR or AHR after ovalbumin inhalation. However, there was a significant cell influx. Sensitisation with 100 micro g OA (single and booster injections) revealed all four parameters of the asthmatic response (EAR, LAR, AHR and cell influx). The incorporation of the booster sensitisation injection resulted in a prolongation of the LAR, and the AHR was more pronounced and cell influx increased significantly, when compared to all other sensitisation protocols. Thus, sensitisation with 100 micro g OA (with a booster injection) can reveal an EAR, LAR, AHR and cell influx following inhalation exposure to OA (10 micro g). Cellular infiltration to the lung may be a poor marker of the asthmatic response, as a threshold level of cell influx (eosinophils) appears to be required in order to elicit the LAR and AHR. There was an association between the LAR and AHR.
在特应性哮喘患者中,吸入抗原会引发早期哮喘反应(EAR),60%的患者还会伴有迟发性哮喘反应(LAR)、气道高反应性(AHR)以及肺部炎症细胞浸润。因此,理想的哮喘动物模型应至少能持续且可重复地呈现这四种特征。本研究的目的是优化卵清蛋白(OA)致敏条件,以便在豚鼠哮喘模型中实现EAR、LAR、AHR和细胞流入。动物分别用10微克或100微克OA进行致敏,采用单次注射或加强注射(第1天和第5天)。通过全身体积描记法测定主动致敏的清醒豚鼠对吸入OA(10微克,1小时)的气道反应,以12小时和24小时内特异性气道传导率(sG(aw))的变化来衡量。吸入组胺(1毫摩尔)引起的支气管收缩用于研究AHR,在激发后24小时通过支气管肺泡灌洗(BAL)测定炎症细胞流入情况。单次用10微克OA致敏后,暴露于OA时未出现EAR、LAR或AHR。然而,与用生理盐水激发的致敏动物相比,激发后24小时的总细胞计数和分类细胞计数(嗜酸性粒细胞和巨噬细胞)显著更高。添加10微克的加强注射后,吸入卵清蛋白后出现了EAR,但没有LAR或AHR。然而,有明显的细胞流入。用100微克OA致敏(单次和加强注射)显示出哮喘反应的所有四个参数(EAR、LAR、AHR和细胞流入)。与所有其他致敏方案相比,加入加强致敏注射导致LAR延长,AHR更明显,细胞流入显著增加。因此,用100微克OA(加强注射)致敏后,吸入暴露于OA(10微克)可出现EAR、LAR、AHR和细胞流入。肺部的细胞浸润可能不是哮喘反应的良好标志物,因为似乎需要一定阈值水平的细胞流入(嗜酸性粒细胞)才能引发LAR和AHR。LAR和AHR之间存在关联。